Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The favor ADC group tended to have a higher percentage of EGFR positivity and ALK positivity than the favor SQC group (25% vs. 11% and 7% vs. 0%, respectively).
|
31494736 |
2019 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy.
|
30885334 |
2019 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this report, we described the first case of squamous cell carcinoma (SCC) transformation from adenocarcinoma (ADC) in NSCLC with ALK rearrangement after treatment with ALK TKI.
|
30642554 |
2019 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Histologic transformation from adenocarcinoma to squamous cell carcinoma in lung cancer has not been reported as a mechanism of resistance to ALK inhibition.
|
30959466 |
2019 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using samples from 122 patients, we established 41 NSCLC PDXs [30 adenocarcinoma (AD), 11 squamous cell carcinoma (SQ)], among which the following driver mutation were observed: 13 EGFR-mutant, 4 ALK-rearrangement, 1 ROS1-rearrangement, 1 PIK3CA-mutant, 1 FGFR1-amplification, and 2 KRAS-mutant.
|
30268457 |
2018 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib.
|
29610932 |
2018 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The development of new targeted drugs based on molecular alterations (EGFR, ALK, and ROS1) has led to important outcome benefits, but not for squamous cell carcinoma (SCC).
|
30025476 |
2018 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To the best of our knowledge, this is the first case report to discuss the successful management of ALK-rearranged lung SqCC with alectinib.
|
28683775 |
2017 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of ALK was significantly different between SCC with ADC (P < 0.001) and LCC samples (P < 0.001).
|
27461700 |
2017 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This work was undertaken to study the prevalence of lung SCC harboring ALK, ROS1, and RET translocations.
|
26973202 |
2016 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The histopathological and immunohistochemical features of this particular tumor highlighting the overlapping criteria between lung adenocarcinomas and rare ALK-rearranged squamous cell lung carcinomas could also be relevant to extend ALK screening to tumors with intermediate phenotypes between squamous cell carcinomas and adenocarcinomas and/or arising in non-smokers.
|
26603857 |
2016 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Even if these abnormalities are seldom detected in squamous cell carcinomas (SQCC), some rare cases of SQCC have been reported to harbor EGFR, ROS1 or ALK genetic alterations with in some cases a response to targeted therapies [2,3].
|
27987587 |
2016 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the response rates have been low for biomarker-directed fibroblast growth factor receptor (FGFR) inhibitor therapy in SCC, which contrasts to the relatively high rates of response seen in EGFR mutant and ALK-translocated lung cancers treated with epidermal growth factor receptor (EGFR) inhibitors and ALK inhibitors, respectively.
|
26549034 |
2016 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ALK rearrangements were detected in 1.7 % in the complete cohort and 2.0 % in the non-squamous cell carcinoma subgroup.
|
27495736 |
2016 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we report a case with squamous cell cancer of lung that harbored the ALK rearrangement was given crizotinib in the second-line therapy.
|
25973127 |
2015 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest the opportunity to test ALK rearrangements on biopsy samples harboring squamous cell cancer differentiation.
|
24722159 |
2014 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the frequency of EML4-ALK rearrangements is lower in lung SqCC than that in lung adenocarcinomas, their presence may provide additional treatment options in lung SqCC.
|
25527865 |
2014 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report the frequency and clinicopathologic features of lung cancers harboring ALK translocations in 594 resected NSCLCs (470 adenocarcinomas; 83 squamous carcinomas, 26 large cell carcinomas and 15 other histological subtypes) using a tissue microarray approach.
|
23743928 |
2013 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
All cases were negative for ALK translocations, while 14/135 (12.1%) of SCCs and 14/116 (10.4%) of ACs showed ALK amplifications.
|
23490651 |
2013 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Spatial proximity between bronchus and ALK-rearranged tumors and frequent solid histologic subtype with p63 expression may cause diagnostic difficulties to differentiate squamous cell carcinoma in the small biopsy, whereas p40 was rarely expressed in ALK-rearranged adenocarcinoma.
|
24194854 |
2013 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas.
|
23568951 |
2013 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We therefore analyzed 102 large-cell carcinomas by immunohistochemistry for TTF-1 and ΔNp63/p40 as classifiers for adenocarcinoma and squamous cell carcinoma, respectively, and correlated the resulting subtypes with nine therapeutically relevant genetic alterations characteristic of adenocarcinoma (EGFR, KRAS, BRAF, MAP2K1/MEK1, NRAS, ERBB2/HER2 mutations and ALK rearrangements) or more common in squamous cell carcinoma (PIK3CA and AKT1 mutations).
|
23196793 |
2013 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS.
|
23423768 |
2013 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ALK translocations were found in 4/151 (2.6%; 3 of them involving EML4) of BM of adenocarcinomas (AC), 1/9 (11.1%) of adenosquamous carcinomas (ASC), 0/5 of squamous cell carcinomas (SCC) and 0/10 of large cell carcinomas (LCC).
|
23453647 |
2013 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry was also performed on an independent cohort consisting of 150 adenocarcinomas and 150 squamous cell carcinomas to evaluate the utility of anaplastic lymphoma kinase immunostaining as a screening tool.
|
19386350 |
2009 |